Member Info for RorkesDrift

Well, I for one can spoll boring

The world of pharma is moving away from stuff in boxes, same drug, same dose approach. Increasingly tailoring medicines time individuals recognising that one size does not fit all.

Skin is a major organ. Akin to our gut, it hosts microorganisms that can benefit or harm. STC enables individuals to ensure that they can achieve the look they are aiming at whilst nurturing and maintaining the health of this organ. Given how much the ladies in my life spend on stuff to prevent aging (I've asked them to keep the receipts) then STC is an investment. I'm guessing it will be one of those snowball products - customers will be the best advocates.

I'm also thinking clinical dermatologists would be a key endorsement route - maybe that channel is next?

Link to gosquidapp?

https://youtu.be/pjvQFtlNQ-M

Thanks for posting. I like...

"Through a licence deal that could generate an upfront payment of tens of millions of dollars. Such a breakthrough would allow the company to roll out a series of innovations for the broader chemotherapy market, which is forecast to be worth more than $50bn by 2024."

Actually a well trodden path that works for everyone. Avacta has to be in discussions - as time goes on, more data accumulated, risks goes down BUT payments go up. For Avacta, AVA006 then has the support of experienced teams. Regulatory, health economics, market access etc. This creates a reference for other products. Current potential milestones for other projects are well in excess of current MKT cap. I guess AS will want to create a buzz about cohort 2 before signing- bit dissapointed no news since implies final read out will be delayed. Could be for all sorts of reasons including maybe no RNS planned. Not concerned - logical to say something with final accounts now maybe.

I'd presumed it was the instruction leaflet - our resident detective attended user trials and from that the company (M19) would have submitted a proposed leaflet. The authorities may have asked for some changes is a cycle of amends - M19/would therefore be aware of where they are in process rather than it being a black hole. Hipe they have good regulatory consultant involved. Normally three languages on one leaflet and for stock management we used to out one big market with two little ones. There are other approaches but each one is checked.

Has MrR missed his nightly fantasy spot the ball and feeling a tad tetchy?

Slightly off track but MABs also have a border effect. They bind to first relevant ligand they hit coupled with their size means tumour penetration is compromised.

Aptamers have been proposed as one way of overcoming this due to their size. Therefore, affimers which are also small offer this potential. Drug conjugates covered by NDAs are part of the Avacta stable.

Excellent.

Just one question. How would Avactas test diagnose a previous infection.

"The Antigen Rapid Saliva Test is intended for screening of populations to diagnose the COVID-19 coronavirus infection, including previous infections."

Oh hang on.......

All that's needed is a bit of positivity.

Investing advice from fun time swing who spends Friday night face down in the red room hoping someone, anyone will enter.

I don't want to say "Don't hold your breath".

I am hoping you might turn BLUE.

Don't take it personally

It sounded like Aptamer Group with more engaged with developing tests for other pathogens beyond Covid. Might be a question of focus or maybe AS is the man who turned down the Beetles.

Interestingly GB sounded very confident that they will be selling 200 units per month - possibly believe it when we see it. China seems to be close to a decision.

Thanks for posting link.

Positive is great if it has a foundation we can understand. Then we can argue and insult each other on the basis of difference of opinion.

Reducing I love Avacta to a football chant disrespects the hard work of Avacta personal and just smacks of greed. If it has to be done just put it in one thread.

In the meantime we await news - cannot see SP moving until then. Unless there is a LEAK.

If it had gone in, it would have been a goal

Someone was posting a series of new (about 6) threads all saying same thing - trying to dominate the top of the board - I was trying to restore it. I'm guessing they were removed this morning.

Thanks for yesterday - I understand why you say venom

https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-12-103

The genuine and the modified Fibonacci sequence determine dose steps (increments). The genuine Fibonacci sequence is defined by the linear recurrence equation Fn=Fn-1+Fn-2, which goes like this: 1, 2, 3, 5, 8, 13, 21, 34, 55, 89… In other words, the next number in the sequence is equal to the sum of its two predecessors.

Phase I methodologists refer commonly to the “so-called modified Fibonacci sequence” [5], which has the followng incremental ratios: 2.00, 1.67, 1.50, and then 1.33 for all subsequent dose-levels. In this form, the incremental ratio tends to a smaller constant number: 1.33

Unless it is a hedge....

https://lmgtfy.app/?q=short+selling+explained

Orph "Only for alcoholics with advanced Liver Cirrhosis might this be a problem"

Fairly self evident that if dox is nephrotoxic then it won't just be alcoholics at risk. We all have some degree of declining renal function as we get older. I think there have been cases of renal failure due to dox.

Note : standard dox therefore also carries a risk of renal AEs but that doesn't stop it being used. Precision is aiming to improve the balance between clinical benefit and risk - for any given "amount" of dox the efficacy goes up.(local release, increasing conc) whilst tolerability (heart, kidneys, liver) remains within therapeutic window.

As yet unproven in either direction - so we accept the potential it might not work whilst also accepting the potential that the preclinical provides strong evidence in three different animal models that it might. Otherwise no need for trial and we all would have made £Ms.

On slightly different note, is 2nd cohort news leaking (heads up the Timster).